RT Journal Article
SR Electronic
T1 Multi-ancestry polygenic risk scores for venous thromboembolism
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.01.09.24300914
DO 10.1101/2024.01.09.24300914
A1 Jee, Yon Ho
A1 Thibord, Florian
A1 Dominguez, Alicia
A1 Sept, Corriene
A1 Boulier, Kristin
A1 Venkateswaran, Vidhya
A1 Ding, Yi
A1 Cherlin, Tess
A1 Verma, Shefali Setia
A1 Faro, Valeria Lo
A1 Bartz, Traci M.
A1 Boland, Anne
A1 Brody, Jennifer A.
A1 Deleuze, Jean-Francois
A1 Emmerich, Joseph
A1 Germain, Marine
A1 Johnson, Andrew D.
A1 Kooperberg, Charles
A1 Morange, Pierre-Emmanuel
A1 Pankratz, Nathan
A1 Psaty, Bruce M.
A1 Reiner, Alexander P.
A1 Smadja, David M.
A1 Sitlani, Colleen M.
A1 Suchon, Pierre
A1 Tang, Weihong
A1 Trégouët, David-Alexandre
A1 Zöllner, Sebastian
A1 Pasaniuc, Bogdan
A1 Damrauer, Scott M.
A1 Sanna, Serena
A1 Snieder, Harold
A1 Lifelines Cohort Study
A1 Kabrhel, Christopher
A1 Smith, Nicholas L.
A1 Kraft, Peter
A1 INVENT Consortium
YR 2024
UL http://medrxiv.org/content/early/2024/01/10/2024.01.09.24300914.abstract
AB Venous thromboembolism (VTE) is a significant contributor to morbidity and mortality, with large disparities in incidence rates between Black and White Americans. Polygenic risk scores (PRSs) limited to variants discovered in genome-wide association studies in European-ancestry samples can identify European-ancestry individuals at high risk of VTE. However, there is limited evidence on whether high-dimensional PRS constructed using more sophisticated methods and more diverse training data can enhance the predictive ability and their utility across diverse populations. We developed PRSs for VTE using summary statistics from the International Network against Venous Thrombosis (INVENT) consortium GWAS meta-analyses of European- (71,771 cases and 1,059,740 controls) and African-ancestry samples (7,482 cases and 129,975 controls). We used LDpred2 and PRSCSx to construct ancestry-specific and multi-ancestry PRSs and evaluated their performance in an independent European- (6,261 cases and 88,238 controls) and African-ancestry sample (1,385 cases and 12,569 controls). Multi-ancestry PRSs with weights tuned in European- and African-ancestry samples, respectively, outperformed ancestry-specific PRSs in European- (PRSCSXEUR: AUC=0.61 (0.60, 0.61), PRSCSX_combinedEUR: AUC=0.61 (0.60, 0.62)) and African-ancestry test samples (PRSCSXAFR: AUC=0.58 (0.57, 0.6), PRSCSX_combinedAFR: AUC=0.59 (0.57, 0.60)). The highest fifth percentile of the best-performing PRS was associated with 1.9-fold and 1.68-fold increased risk for VTE among European- and African-ancestry subjects, respectively, relative to those in the middle stratum. These findings suggest that the multi-ancestry PRS may be used to identify individuals at highest risk for VTE and provide guidance for the most effective treatment strategy across diverse populations.Competing Interest StatementB.M.P. serves on the Steering Committee of the Yale Open Data Access Project funded by Johnson & JOhnson. S.M.D. receives research support from RenalytixAI and Novo Nordisk, outside the scope of the current research. SMD is named as a co-inventor on a Government-owned US Patent application related to the use of genetic risk prediction for venous thromboembolic disease filed by the US Department of Veterans Affairs in accordance with Federal regulatory requirements.Funding StatementThis work was supported by the National Institutes of Health grant 5U01CA261339.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol was approved by Mass General Brigham IRB: 2013P000713.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced are available online at https://github.com/yonhojee/VTE_PRS. https://github.com/yonhojee/VTE_PRS